Botond Literáti-Nagy

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Improvement of Insulin Sensitivity by a Novel Drug, BGP-15, in Insulin-resistant Patients: A Proof of Concept Randomized Double-blind Clinical Trial

Botond Literáti-Nagy, Enikő Kulcsár, Zs. Literáti-Nagy et al. · Hormone and Metabolic Research · 2009 · 112 citations

Serum osteocalcin is associated with improved metabolic state via adiponectin in females versus testosterone in males. Gender specific nature of the bone–energy homeostasis axis

Barbara Buday, Ferenc Péter Pach, Botond Literáti-Nagy et al. · Bone · 2013 · 45 citations

Metabolic Syndrome, Gender Specific Nature, Bone Health +14

Improvement of Insulin Sensitivity by a Novel Drug Candidate, BGP-15, in Different Animal Studies

Botond Literáti-Nagy, Kálmán Tory, Barna Peitl et al. · Metabolic Syndrome and Related Disorders · 2014 · 35 citations